Eli Lilly Stock Slips on FDA Approval Delay

Eli Lilly and Co (NYSE:LLY) stock is slipping today, after the U.S. Food & Drug Administration (FDA) delayed approving the drugmaker's Alzheimer’s drug, donanemab, which was expected to be approved this month, and called for an advisory panel. At last glance, LLY was down 1.7% at $766.79. LLY has consistently seen record highs in 2024, most recently hitting a Mar. 4 all-time peak of $800.78. The stock's 20-day moving average has guided the shares higher since the start of the year, and is capturing today's ...